| Patient | Ernest Shackleton |
|---|---|
| Date of birth | 1979-02-15 |
| Identifiers | MRN HR-EX001-SYN; SSN (made up) 000-01-7763 |
| Document date | 2026-06-23 |
| Author | Cormac Ellingsworth-Daly, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review of angina on medical therapy; decision about coronary angiography. [S]
Mr. Shackleton returns four weeks after his consultation. On metoprolol 100 mg his resting pulse is 60, but he still has chest tightness two or three times a week when he climbs the stairs carrying papers or walks fast into a cold wind, and he has used nitroglycerin four times. It never comes at rest. He has not smoked for five weeks. He is drinking within the limit he agreed. He sails in under three months, will be lifting and hauling at sea, and will be weeks from a hospital. He asked whether a stent would let him do that. He was uneasy about having a procedure that the backers might hear of, and said so; after talking it through he wants to go ahead. [S]
| Element | Detail |
|---|---|
| Angina | Two or three episodes a week despite metoprolol 100 mg |
| Nitroglycerin | Used four times |
| Tobacco | Not smoked for five weeks |
| Goal | To lead the expedition without angina limiting him |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Exertional angina unchanged in frequency; no rest pain or fainting |
| Respiratory | Negative | No cough or breathlessness apart from the angina |
| Gastrointestinal | Negative | Nausea on varenicline gone; no bleeding |
| Musculoskeletal | Negative | No muscle aches on the statin |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 2026-05-12 | active | S |
| Atorvastatin 80 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-05-12 | active | S |
| Metoprolol succinate extended-release 50 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-05-12 to 2026-05-26 | stopped | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses | as needed for chest pain, up to 3 doses | Sublingual route | 2026-05-12 | active | S |
| Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration | twice a day after titration | Oral route | 2026-05-12 | active | S |
| Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-05-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-23 | Body height | 175 | cm | S |
| 2026-06-23 | Body weight | 85 | kg | S |
| 2026-06-23 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 2026-06-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-06-23 | Heart rate | 60 | /min | S |
| 2026-06-23 | Respiratory rate | 14 | /min | S |
| 2026-06-23 | Body temperature | 36.6 | Cel | S |
| 2026-06-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-23 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-23 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-06-23 | Hemoglobin [Mass/volume] in Blood | 15.6 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-06-23 | Platelets [#/volume] in Blood by Automated count | 245 | 10*3/uL | 140-400 10*3/uL | Normal | S |
| 2026-06-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 98 | mL/min/{1.73_m2} | 60 or more | Normal | S |
Vital signs recorded on 2026-06-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 128/80, pulse 60, weight 85.0 kg |
| Cardiovascular | Regular rhythm; no murmur; both radial pulses normal, Allen test normal on the right |
| Respiratory | Clear to auscultation bilaterally |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chest tightness and breathlessness on exertion for about three months, brought on by stairs, carrying loads, and walking fast in cold wind and relieved within minutes by rest, never at rest; resting ECG normal; cause not yet established at intake; coronary CT angiography and cardiology consultation requested | resolved | confirmed | R07.89 | S — Synthetic presenting problem anchored to his documented exertional breathlessness; superseded by the diagnosis at the cardiology consultation. |
| Nicotine dependence, cigarettes: about 25 a day since 16 (about 39 pack-years) | active | confirmed | F17.210 | S — Synthetic modern coding anchored to his documented heavy smoking. |
| Chronic coronary disease with stable exertional angina: 80% stenosis of the proximal left anterior descending artery with CT-FFR 0.70, mild right coronary artery disease, coronary calcium score 210, and normal left ventricular function; synthetic modern episode linked to his documented exertional illnesses and the coronary atheroma recorded at his death | active | confirmed | I25.118 | S — Synthetic modern diagnosis made at the cardiology consultation; Macklin's coronary diagnosis is recorded in CLM-0009 and the alternative theories as R. |
| Hyperlipidemia: LDL cholesterol 168 mg/dL and HDL 38 mg/dL at intake | active | confirmed | E78.5 | S — Synthetic modern risk factor; no historical measurement exists. |
| Prediabetes: HbA1c 5.9% at intake | active | confirmed | R73.03 | S — Synthetic modern risk factor; no historical measurement exists. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 128/80 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 85.0 kg; walking more |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | Class II despite optimized beta-blocker; nitroglycerin four times |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | All taken daily; resting pulse 60 on metoprolol 100 mg |
| Imaging | Invasive coronary angiography with a view to revascularization | For angina that persists despite guideline-directed medical therapy, or by shared decision | Ordered | Booked for next week after a shared decision |
| Laboratory | Creatinine, eGFR, potassium, hemoglobin, and platelets before angiography | Before contrast and antiplatelet loading | Completed today | Creatinine 0.96 mg/dL (eGFR 98), potassium 4.3 mmol/L, hemoglobin 15.6 g/dL, platelets 245 thousand per microliter |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | No repeat noninvasive imaging; anatomy already defined |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Due | At ten weeks on atorvastatin, at the next visit |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for five weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | Within the agreed limit by his report; AUDIT-C at the next visit |
| Referral | Cardiac rehabilitation referral | At diagnosis of stable angina, and after PCI | Deferred | Still not made; to be made after the stent |
Goal progress:
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023); 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018)
Follow-up: Coronary angiography next week. Review three weeks after the procedure with a lipid panel. Next scheduled visit 2026-07-21: ten-week review: three weeks after the stent, lipids, cardiac rehabilitation, smoking and alcohol. [S]